, FemTech III is Actively Investing!

Portfolia’s 2024 Performance Reports are now available for all funds. COO Tammi Jantzen will present an overview April 3rd on Understanding Performance Reports and K-1s. Register Now to secure your spot.

Live and interactive meetings will be held for Fund Members with Fund management teams from April 20 to May 15. Stay tuned for detailed schedules.

Join the Waitlist

The Portfolia Investor Summit has officially reached capacity. If you’d like to join us, please add your information below. We will be in touch if space becomes available.

As we focus on performance, the Rising America Funds continue to be among our highest performers with Fund I in the top 5% of all venture capital funds of its vintage year.  With a strong focus in healthcare and fintech, secure your spot now in Rising America Fund III.

FemTech Fund III is a new 2023 vintage year fund and still deploying capital.  According to Cambridge Associates, funds formed since 2023 are too young to have produced meaningful returns. FemTech Fund III invested in 9 portfolio companies as of 12/31/24 and expects to invest in a total of 14-16 companies.

Annual Fund Performance Report

2024 FemTech III Fund Performance Updates

The 2024 financial statements are as of and for December 31, 2024. Please note all updates provided are confidential and not for distribution. To access the file, use password:

2024FT3Report!

Quarterly Reports

The highlights of Q4 2024 updates as provided by the company. Please note all updates provided are confidential and not for distribution.

To access the file, use password: Q424FT3!

Upcoming Pitch Call

April 9, 2025 | 9:30 AM PT

Every month, members will have the opportunity to join in on the pitch calls with other members and our lead partners. We always welcome your business questions and consumer expertise, but if you can’t attend, you’ll always be able to listen to the recording on your dashboard when it’s more convenient.

Missed the last pitch call? Catch up here!

FemTech III Portfolio Highlights

The Companies & Leadership Team

The Portfolia FemTech III Fund is led by a world-class team of highly sophisticated and experienced investors who are leaders in their respective fields, as venture capitalists, angel investors, and innovators. They bring an expert skill-set including sourcing, diligence, deal negotiation, executive recruitment, strategy and governance. Click on photos for full bios.

The Companies

Company Logo Gallery
Apollo Neuroscience

Apollo Neuro offers a wearable consumer wellness device intended to help manage stress, challenging life transitions, and to promote a healthy lifestyle.

Attn: Grace

Attn Grace is a sustainable wellness brand designed for women, creating more sustainable solutions for women to combat bladder leakage.

Inherent Biosciences

A molecular diagnostics company at the intersection of epigenetics and AI tackling clinical problems where epigenetics appears to be involved such as infertility.

Maude

Maude is setting new standards for sexual wellness and works closely with factories to create body-safe, accessible essentials for all.

FemDx

FEMDX is a developer of cancer diagnosis devices designed to detect ovarian cancer.

Simple HealthKit

Simple Health Kit provides high-quality, accessible, and affordable diagnostic services for chronic health conditions.

Neuspera

Neuspera develops ultra-miniaturized, implantable medical devices for treating chronic conditions such as Overactive Bladder (OAB).

Hera Biotech

Developer of definitive tissue-based tests designed to diagnose and stage endometriosis.

Portfolia Lead Partners

Featured
Dr. Faz Bashi
Dr. Faz Bashi

FemTech I and II

Investment Lead: Future Family, Maven Clinic, Joylux, Nest Collaborative

-Founding Member, Healthtech Capital

-Angel Capital Association Life Sciences Syndication Group Chair

-Advisor, One Health Group

Delphine O’Rourke
Delphine O’Rourke

FemTech III

-President & Chief Executive Officer of Safe & Green Medical

-Partner at Goodwin Procter LLP

-Board of the Columbia Law School Alumni Association

Jennifer Fried
Jennifer Fried

FemTech II & III

Investment Lead: Willow, YourChoice, Proov, Aria CV

-CEO & Co-Founder of ExplORer Surgical

-Previously at Park Lane Ventures, helthcare-focused fund

Lauri Kien Kotcher
Lauri Kien Kotcher

FemTech I, II & III

Investment Lead: Attn: Grace, Hey Jane, Madison Reed

-Former CEO of Hello Products

-Former CMO of Godiva

-Former Head of Global Brands at Pfizer Consumer Healthcare.

-Advisory board member, Springboard Enterprises & The New York Fashion Tech Lab

Nola Masterson
Nola Masterson

FemTech I,II & III

Investment Lead: Aeena, Bone Health Technologies, Inherent Biosciences, xCures

-California Life Sciences Institute, Chair Emeritus

-Co-Founder and first CEO of Sequenom

-45+ years in the life sciences industry and in venture investments

Companies In Diligence

If there are no companies in diligence currently, you can still volunteer and we'll contact you when a new one is being assembled

Featured
Clear Gene’s tests help eradicate cancer by telling doctors whether they got it all, at a curable stage. The company is starting with breast cancer using advances in data science to analyze gene activity, which promises to save thousands of lives an

Clear Gene’s tests help eradicate cancer by telling doctors whether they got it all, at a curable stage. The company is starting with breast cancer using advances in data science to analyze gene activity, which promises to save thousands of lives and $3 billion in annual healthcare costs.

Materna is a medical technology company transforming the standard of care in OBGYN with core technologies addressing unmet needs developing products (Milli and Materna Prep) to improve women's pelvic and sexual health. 

Materna is a medical technology company transforming the standard of care in OBGYN with core technologies addressing unmet needs developing products (Milli and Materna Prep) to improve women's pelvic and sexual health. 

Phiogen has developed a world-first technology platform that mobilizes the natural power of bacteriophages to tackle critical and life-threatening infections. Company deck is linked here .

Phiogen has developed a world-first technology platform that mobilizes the natural power of bacteriophages to tackle critical and life-threatening infections. Company deck is linked here.

Healing formula designed for women prone to vaginal irritation, discomfort, and pain. Maintain vaginal health & ease pain with Naked Love, the first clinically-proven lubricant. Company deck is linked here .

Healing formula designed for women prone to vaginal irritation, discomfort, and pain. Maintain vaginal health & ease pain with Naked Love, the first clinically-proven lubricant. Company deck is linked here.

Kaida is dedicated to providing patients with treatment-resistant gynecological cancers. Their mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant diff

Kaida is dedicated to providing patients with treatment-resistant gynecological cancers. Their mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference.

Refer A Company

The FemTech III fund will invest in 8-12 companies, from Seed to pre-IPO. We consider companies with solutions in the market, and we invest in both female- and male-led teams with a preference for gender-balanced executive teams. We only invest in companies with a U.S.-based C-Corp. Please submit the company information below or email companies@portfolia.com with questions.

Interested in other funds?

Connect with Investor Relations at investorrelations@portfolia.com

Additional questions?

Reach out to our team at members@portfolia.com